Clinics最新文献

{"title":"Behavioral therapies for the treatment of autism spectrum disorder: A systematic review","authors":"Clara Lucato dos Santos ,&nbsp;Indyanara Inacio Barreto ,&nbsp;Ana Carolina Furian da Silva ,&nbsp;Juliana Firmino Batista Soriano ,&nbsp;Jeferson de Lima Silva Castro ,&nbsp;Luca Schiliró Tristão ,&nbsp;Wanderley Marques Bernardo","doi":"10.1016/j.clinsp.2024.100566","DOIUrl":"10.1016/j.clinsp.2024.100566","url":null,"abstract":"<div><h3>Introduction</h3><div>Autism Spectrum Disorder (ASD) is a neurodevelopment spectrum characterized by persistent deficits in social communication and interpersonal interaction, along with restricted and repetitive patterns of behavior, interest, or activities. The appropriate screening and diagnosis must be realized to improve the children's prognosis. Moreover, appropriate treatments are necessary to promote better social integration and development. In this scenario, this systematic review aims to evaluate the impacts of behavioral therapies applied in healthcare settings for patients with ASD.</div></div><div><h3>Methods</h3><div>This systematic review followed the PRISMA guidelines. The databases MEDLINE, Embase, CENTRAL (Cochrane), and Lilacs were accessed, and gray and manual searches were performed. The search strategy was created with terms referring to autism and behavioral therapy. The studies were assessed qualitatively.</div></div><div><h3>Results</h3><div>Randomized clinical trials and observational studies demonstrated improvements in cognitive and verbal components of patients who received behavioral therapies in therapeutic settings. These results indicate a positive impact of both cognitive-behavioral therapy and ESDM on the development of patients’ skills. Among the cognitive-behavioral therapies, the one based on the MASSI protocol did not impact the reduction of anxious symptoms. As for cognitive-behavioral therapy, one study demonstrated that the Behavioral Intervention for Anxiety in Children with Autism (BIACA), when compared to the Coping Cat protocol, improves cognition and reduces anxiety symptoms. Despite these results, further randomized clinical trials comparing behavioral therapies with one another are needed.</div></div><div><h3>Conclusion</h3><div>In the context of behavioral therapy within a healthcare setting, the Early Start Denver Model (ESDM) showed improvements in the cognitive, verbal, and social aspects of the evaluated patients. Improvement in scores sometimes is achieved independently of the group and related to the time of interventions.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100566"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agreement analysis and associated factors of SARC-F and SARC-CALF in screening of risk sarcopenia in people living with human immunodeficiency virus","authors":"Lara Cristina Vieira ,&nbsp;Jaine Alves Ximenez ,&nbsp;Maria Claudia Bernardes Spexoto","doi":"10.1016/j.clinsp.2024.100565","DOIUrl":"10.1016/j.clinsp.2024.100565","url":null,"abstract":"<div><h3>Introduction</h3><div>People Living with Human Immunodeficiency Virus (PLHIV) appear to be at a higher risk of developing sarcopenia. Various factors seem to influence the risk of sarcopenia, and its prevalence may differ depending on the screening tool used. This study aimed to (i) Screen the risk of sarcopenia in PLHIV using the SARC-F and SARC<img>Calf and identify associated factors; (ii) Analyze the agreement between the instruments in PLHIV.</div></div><div><h3>Methods</h3><div>Cross-sectional study including PLHIV taking antiretroviral therapy. The authors assessed sarcopenia risk using the SARC-F and SARC<img>Calf tools with ≥4 and ≥11 cutoff points, respectively, and a wide spectrum of variables was analyzed.</div></div><div><h3>Results</h3><div>Participated 76 patients (44.9 ± 12.7 years). Sarcopenia risk, according to the SARC-F, was 27.6 % and was associated with socioeconomic status (<em>p</em> = 0.004), smoking (<em>p</em> = 0.001), disease status (<em>p</em> &lt; 0.001), opportunistic infections (<em>p</em> = 0.001), CD4 T-cell count (<em>p</em> &lt; 0.001), Handgrip Strength (HGS) (<em>p</em> &lt; 0.001), and Gait Speed (GS) (<em>p</em> = 0,001). Using the SARC<img>Calf, sarcopenia risk was 36.8 % and was associated with work activity (<em>p</em> = 0.029), socioeconomic status (<em>p</em> = 0.004), smoking (<em>p</em> = 0.009), disease status (<em>p</em> &lt; 0.001), opportunistic infections (<em>p</em> = 0.015), CD4 T-cell count (<em>p</em> = 0.002), HGS (<em>p</em> = 0.001), Appendicular Skeletal Muscle Mass Index (ASMMI) (<em>p</em> = 0.009), and GS (<em>p</em> &lt; 0.001). The agreement between tools was moderate (<em>k</em> = 0.49).</div></div><div><h3>Conclusion</h3><div>Sarcopenia risk, as determined by both tools, was higher in low-income PLHIV with opportunistic infections, CD4 T-cell count ≤ 200 cells/mm³, low HGS, and low GS, and lower in asymptomatic and non-smoking individuals. The authors recommend investigating these factors in hospital and outpatient settings. The SARC<img>Calf proved to be more appropriate for screening sarcopenia risk in PLHIV.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100565"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OSVE or multiple-choice test: Is that a relevant question?","authors":"Francine Jomara Lopes ,&nbsp;Renato Fraga Righetti ,&nbsp;Matheus Belloni Torsani ,&nbsp;Gustavo Silva Azevedo ,&nbsp;Fernando Mauad Sacramento ,&nbsp;Iolanda de Fátima Lopes Calvo Tibério","doi":"10.1016/j.clinsp.2024.100519","DOIUrl":"10.1016/j.clinsp.2024.100519","url":null,"abstract":"<div><h3>Introduction</h3><div>The OSCE has been a robust tool for assessing clinical skills in medical education, adaptable across various clinical domains and stages. The COVID-19 pandemic, however, posed significant challenges to traditional assessment methods. This led to the development of the OSVE as an alternative.</div></div><div><h3>Objective</h3><div>This study aimed to correlate OSVE results with MCT scores and Grade Point Average (GPA) of clerkship.</div></div><div><h3>Methods</h3><div>This cross-sectional study involved 129 clerkships. It compared two OSVEs and two MCTs, covering content from the 5th and 6th years of the curriculum, against final graduation grades.</div></div><div><h3>Results</h3><div>The score of GPA was 8.13 ± 0.43. The authors compared OSVE-5th (7.13 ± 0.93) and OSVE-6th (7.23 ± 0.83, NS), MCT-5th (7.08 ± 0.91) vs. MCT-6th (7.68 ± 1.21, <em>p</em> &lt; 0.001), OSVE-5th (7.13 ± 0.93) and MCT-5th (7.08 ± 0.91, NS), OSVE-6th (7.23 ± 0.83) and MCT-6th (7.68 ± 1.21, <em>p</em> &lt; 0.001) OSVE-5th (7.13 ± 0.93) and MCT-6th (7.68 ± 1.21, <em>p</em> &lt; 0.001), OSVE-6th (7.23 ± 0.83) and MCT-5th (7.08 ± 0.91, NS), OSVE-5th (7.13 ± 0.93) and GPA (8.13 ± 0.43, <em>p</em> &lt; 0.001), OSVE-6th (7.23 ± 0.83) and GPA (8.13 ± 0.43, <em>p</em> &lt; 0.001), MCT-5th (7.08 ± 0.91) and GPA (8.13 ± 0.43, <em>p</em> &lt; 0.001), and MCT-6th (7.68 ± 1.21) and GPA (8.13 ± 0.43, <em>p</em> &lt; 0.001). There were positive correlations between OSVE-5th and OSVE-6th (<em>R</em> = 0.418, <em>p</em> &lt; 0.05), OSVE-5th and MCT-5th (<em>R</em> = 0.475, <em>p</em> &lt; 0.05), MCT-5th, OSVE-6th and MCT-6th (<em>R</em> = 0,180, <em>p</em> &lt; 0.05), MCT-6th (<em>R</em> = 0.227, <em>p</em> &lt; 0.05), with OSVE-6th and MCT-5th (<em>R</em> = 0.478, <em>p</em> &lt; 0.05), OSVE-5th and GPA (<em>R</em> = 0.481, <em>p</em> &lt; 0.05), OSVE-6th and GPA (<em>R</em> = 0,439, <em>p</em> &lt; 0.05), MCT-5th and GPA (<em>R</em> = 0.681, <em>p</em> &lt; 0.05) and MCT-6th and GPA (<em>R</em> = 0.195, <em>p</em> &lt; 0.05), no correlation was found between OSVE-6th and MCT-6th (<em>R</em> = 0.070, NS).</div></div><div><h3>Conclusions</h3><div>The correlations between the assessments revealed mild to moderate, suggesting that the assessments can be used interchangeably in the context of formative assessment. These results indicate the feasibility of using both OSVE and multiple-choice tests as effective tools to enhance intern training and monitoring<strong>.</strong></div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100519"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Power Doppler in hand joints predicts therapeutic failure in treatment-naive women with early rheumatoid arthritis: A prospective study","authors":"Karine Rodrigues da Luz ,&nbsp;Jamil Natour ,&nbsp;Marcelo de Medeiros Pinheiro ,&nbsp;Giovanna S. Petterle ,&nbsp;Marla Francisca dos Santos ,&nbsp;Artur da Rocha Correa Fernandes ,&nbsp;Rita Nely Vilar Furtado","doi":"10.1016/j.clinsp.2025.100593","DOIUrl":"10.1016/j.clinsp.2025.100593","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to determine whether ultrasound measurements of the hands could predict treatment failure in treatment-naive women with early rheumatoid arthritis.</div></div><div><h3>Method</h3><div>In a prospective case-control study, 48 women underwent blind assessments four times over 48-weeks, considering three failure stages: failure 1 (methotrexate), failure 2 (leflunomide), and failure 3 (adalimumab). Bilateral ultrasound exams evaluated wrist, 2nd, and 3rd Metacarpophalangeal Joints (MCPs), and Proximal Interphalangeal Joints (PIPs) for inflammatory indicators (synovial and tenosynovial proliferation using grayscale and Power Doppler [PD]) and joint damage (bone erosion and cartilage damage).</div></div><div><h3>Results</h3><div>The study involved 48 women, aged 47.7 ± 11.6 years, with an average disease duration of 7.5 ± 3.5 months. Of these, 41 (85.41 %) experienced failure 1, 25 (52 %) experienced failure 2, and 5 (10.5%) experienced failure 3. Predictors for failure 1 included PD/Q10 total score &gt; 2.5 (OR = 18.00), PD/SQ10 total score &gt; 5.0 (OR = 23.2), PD/Q MCP score &gt; 1.5 (OR = 14.58), and PD/SQ MCP score &gt; 3.0 (OR = 35). For failure 2, predictors encompassed PD/Q10 total score &gt; 4.5 (OR = 4.81), PD/SQ10 total score &gt; 9.5 (OR = 4.81), PD/Q MCP score &gt; 2.5 (OR = 4.92), PD/SQ MCP score &gt;5.0 (OR = 6.22), and PD/Q PIP score &gt; 1.5 (OR = 6.66). In relation to failure 3, a PD/Q wrist score &gt; 2.5 (AUC = 0.79; <em>p</em> = 0.035) was indicative.</div></div><div><h3>Conclusions</h3><div>Power Doppler proved to be a predictive indicator for treatment failure in early rheumatoid arthritis among treatment-naive women. It emerged as a predictor for both the initial and 2nd DMARD treatments, as well as the 1st immunobiological treatment, based on hand joint assessments.</div></div><div><h3>Trial registration</h3><div>Clinical trials.gov NCT04752748.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100593"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143526995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of contrast-enhanced ultrasound combined with serum procalcitonin in tuberculous lymph nodes and metastatic lymph nodes","authors":"Lin Li ,&nbsp;Lan He ,&nbsp;Minchao Xiong ,&nbsp;Xiaoyan Wang","doi":"10.1016/j.clinsp.2024.100541","DOIUrl":"10.1016/j.clinsp.2024.100541","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the value of Contrast-Enhanced Ultrasound (CEUS) combined with Procalcitonin (PCT) in differentiating Tuberculous Lymph Nodes (TLN) from Metastatic Lymph Nodes (MLN).</div></div><div><h3>Methods</h3><div>This prospective cohort study included 207 consecutive patients diagnosed with CTL. Before confirming through pathology or laboratory tests, every patient received standard ultrasound, CEUS, and MRI examinations, with the imaging results analyzed afterward. Serum indicators were measured by Enzyme-Linked Immunosorbent Assay (ELISA). Predictive modeling was performed by multifactorial logistic regression. Evaluate the diagnostic and calibration performance of the predictive model by drawing Receiver Operating Characteristic (ROC) curves and calibration curves, and using Area Under the Curve (AUC) and Hosmer-Lemeshow (H-L) tests.</div></div><div><h3>Results</h3><div>The presence of lymph node lesions was confirmed by routine ultrasound and MRI in 207 patients, of which 102 (49.27 %) had a pathological or laboratory diagnosis of metastatic lymph nodes (MLN), and 50.8 % were tuberculous lymph nodes (TLN). According to imaging findings of CEUS, TLN was more commonly associated with enhanced concentric performance in the arterial phase (67.65 % vs. 40.95 %) and heterogeneous enhancement pattern in lymph nodes (70.59 % vs. 52.38 %). Peak Intensity (PI) of lesions was higher in patients with MLN. Increased age-enhanced concentric performance in the arterial phase, increased PI, and serum PCT greater than 5.39 ng/mL were independent risk factors for MLN. The prediction model of serum PCT combined with CEUS had a higher diagnostic value for MLN. The H-L test indicated a satisfactory model fit (all p &gt; 0.05), and the calibration curve closely approximates the ideal diagonal.</div></div><div><h3>Conclusion</h3><div>CEUS combined with serum PCT has better clinical application value in the differential diagnosis of TLN and MLN.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100541"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged high Myl9 levels are associated with the pathogenesis and respiratory symptom of post-acute COVID-19 syndrome: A 6-month follow-up study","authors":"Jun Sugihara ,&nbsp;Chiaki Iwamura ,&nbsp;Tomoya Tateishi ,&nbsp;Tadashi Hosoya ,&nbsp;Sho Shimada ,&nbsp;Kiyoshi Hirahara ,&nbsp;Shinsuke Yasuda ,&nbsp;Yasunari Miyazaki","doi":"10.1016/j.clinsp.2025.100584","DOIUrl":"10.1016/j.clinsp.2025.100584","url":null,"abstract":"<div><h3>Background</h3><div>Post-acute COVID-19 Syndrome (PACS) occurs in some COVID-19 patients long after acute infection and significantly affects patients’ health. However, the mechanism by which PACS develops is unknown. Myosin light chain 9 (Myl9), produced by activated platelets, plays a role in immune dysregulation and microthrombi formation during acute COVID-19. However, in the PACS phase, the association between Myl9 and residual symptoms remains unclear, and further investigation is needed.</div></div><div><h3>Methods</h3><div>In this prospective cohort study, serum Myl9 concentrations were measured in 195 COVID-19 patients during hospitalization and at 3- and 6-month follow-up visits. Gaussian mixture modeling was used to identify groups on the basis of Myl9 levels. Relationships between Myl9 levels and residual symptoms were evaluated. Clinical characteristics influencing Myl9 levels were analyzed via logistic regression.</div></div><div><h3>Results</h3><div>A total of 304 serum samples from 195 patients were collected. Two distinct groups were identified in the Myl9 distribution with a cutoff of 386 ng/mL by Gaussian mixture modeling in this cohort. The high-Myl9 group presented significant residual respiratory symptoms at 6 months post-infection (<em>p</em> &lt; 0.05). Elevated Myl9 levels at 6 months were correlated with increased neutrophil counts (<em>p</em> &lt; 0.01) and respiratory comorbidities at diagnosis (<em>p</em> &lt; 0.05) according to univariate regression analysis. Multivariate regression analysis confirmed the relationship between the neutrophil count and high Myl9 levels.</div></div><div><h3>Conclusion</h3><div>Prolonged high Myl9 levels are associated with respiratory symptoms, suggesting the potential involvement of prolonged inflammation or endothelial damage in PACS.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100584"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hearing loss and small and large fibre neuropathy associated with the heterozygous variants c.20A>T in HBB and del-3.7 in HBA","authors":"Josef Finsterer ,&nbsp;Fulvio A. Scorza ,&nbsp;Carla A. Scorza ,&nbsp;Ana C. Fiorini","doi":"10.1016/j.clinsp.2025.100597","DOIUrl":"10.1016/j.clinsp.2025.100597","url":null,"abstract":"","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100597"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab in gestational trophoblastic neoplasia: Systematic review and meta-analysis with sub-group analysis of potential prognostic factors","authors":"Marcio Barcellos ,&nbsp;Antonio Braga ,&nbsp;Matheus Machado Rech ,&nbsp;Solange Artimos de Oliveira ,&nbsp;Jose Mauro Madi ,&nbsp;Sue Yazaki Sun ,&nbsp;Jorge de Rezende-Filho ,&nbsp;Kevin M. Elias ,&nbsp;Neil S. Horowitz ,&nbsp;Ross S. Berkowitz","doi":"10.1016/j.clinsp.2025.100583","DOIUrl":"10.1016/j.clinsp.2025.100583","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the performance of pembrolizumab for the treatment of Gestational Trophoblastic Neoplasia (GTN).</div></div><div><h3>Methods</h3><div>The Medical Subject Headings related to immunotherapy/pembrolizumab and GTN were used alone or in combination to retrieve relevant articles. The authors searched in EMBASE, MEDLINE/PubMed, Elsevier's Scopus, and Web of Science until November/2024. The authors included any randomized controlled trials, cohort studies, case series, and case reports focusing on pembrolizumab treatment in GTN. Meta-analysis of proportions was carried out employing a random-effects model. The meta-analysis employed the inverse variance method, with the arcsine link function for the analysis of proportional data. All analyses were performed using Stata 18. For all analyses, a p-value &lt; 0.05 indicated statistical significance. This study was registered on PROSPERO (CRD42023493329).</div></div><div><h3>Results</h3><div>A total of 550 studies were identified after a literature search among which 15 original studies were included in the systematic review and in the meta-analysis. Pembrolizumab induced complete sustained remission in 71.59% (95% CI 53.27‒84.78%; I² = 0.00%, H² = 1.00, p = 0.90) of cases. The subgroups meta-analysis showed pembrolizumab had similar performance, regardless of age (&lt; 40 vs. ≥ 40-years-old, p = 0.38), GTN histopathology (Placental Site Trophoblastic Tumor [PSTT], Epithelioid Trophoblastic Tumor [ETT]/noninvasive mole/others versus invasive mole/choriocarcinoma, p = 0.48), time from diagnosis to the beginning of immunotherapy (&lt; 4 vs. ≥ 4-years, p = 0.84), pembrolizumab combined with chemotherapy (yes vs. no, p = 0.66).</div></div><div><h3>Conclusions</h3><div>Pembrolizumab seems an effective treatment for patients with high-risk GTN with chemoresistant or relapsed disease, including cases of PSTT/ETT, notwithstanding patient age, time to initiate immunotherapy and whether or not it was associated with chemotherapy.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100583"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143526870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical study of the effect of mometasone furoate nasal spray treatment on hearing and in secretory otitis media in children","authors":"Xiaoyan Yu,&nbsp;Lang Xu,&nbsp;Youqi Xie,&nbsp;Mengjie Huang","doi":"10.1016/j.clinsp.2024.100551","DOIUrl":"10.1016/j.clinsp.2024.100551","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the effect of Mometasone furoate (Elocon Cream) Nasal Spray (MFNS) treatment on hearing secretory Otitis Media (SOM) in younger children.</div></div><div><h3>Methods</h3><div>Seventy-six children with SOM (ages 5 to 10 years-old) were selected as study subjects and divided into two groups of 38 cases each using a randomized numerical table. The control group was given conventional treatment, and the observation group was treated with MFNS based on the control group. Both groups were treated for 12 weeks. The improvements in clinical symptoms and hearing were compared between the two groups at weeks 4, 8 and 12 of treatment, respectively.</div></div><div><h3>Results</h3><div>The total effective rate of treatment in the observation group was higher than that in the control group. The middle ear resonance frequency of the children in the observation group was higher than that of the control group at weeks 4, 8 and 12 of treatment, and the air-conduction hearing threshold was lower than that of the control group. The total effective rate of the observation group after 12-weeks of treatment was 92.11 %, which was significantly higher than that of the control group (73.68 %). In addition, the T-ETDQ score of the observation group was lower than that of the control group after treatment.</div></div><div><h3>Conclusion</h3><div>MFNS has clinical efficacy in the treatment of SOM in young children, which can improve clinical symptoms, promote the recovery of hearing and eustachian tube function, reduce the local inflammatory response, and improve immune function.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100551"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CST1 promoted gastric cancer development by activating the AKT pathway","authors":"Lei Zhang ,&nbsp;Dongmei Wang ,&nbsp;Liqun Zhang ,&nbsp;Lini Zhu","doi":"10.1016/j.clinsp.2024.100561","DOIUrl":"10.1016/j.clinsp.2024.100561","url":null,"abstract":"<div><h3>Background</h3><div>Gastric Cancer (GC) was the third highest mortality rate among malignant tumors. Currently, no specific treatment is utilized to prevent the progression of GC. The detailed mechanism of GC was still elusive and this study aimed to clarify the mechanism of GC occurrence and development.</div></div><div><h3>Method</h3><div>This study was performed to clarify the molecular mechanisms of CST1 promoting GC development through activating AKT. The normal gastric tissue cells and GC cell was obtained, followed by transfection with oe-CST1 or sh-CST1, and their apoptosis and viability were evaluated. Finally, Western blot, Flow cytometry assay, Transwell assay, and Scratch assay were used to elucidate the molecular mechanisms of CST1 promoting GC development through activating the AKT pathway.</div></div><div><h3>Results</h3><div>Research outcomes show a significant elevation in CST1 and AKT protein as well as mRNA quantities in both the model and CST1-activator cohorts in relation to the control. Conversely, these proteins and mRNA concentrations were notably decreased in the presence of the CST1 inhibitor when compared to the model group, a difference that was statistically significant as evidenced by the <em>p</em>-value.</div></div><div><h3>Conclusion</h3><div>CST1 can promote the gastric cancer process by targeting the AKT pathway.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100561"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}